<DOC>
	<DOCNO>NCT01022970</DOCNO>
	<brief_summary>This study design investigate effect 12 week course intravenous QAX576 6mg/kg every 4 week reduce number eosinophil esophagus EoE patient 75 % great compare baseline .</brief_summary>
	<brief_title>Efficacy Safety QAX576 Patients With Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Males female age 1850 symptomatic eosinophilic esophagitis Female subject must woman non child bear potential . Elimination diet must try . Treatment least two month prior enrollment protocol pump inhibitor . Appropriate contraception must use male , ( e.g. , spermicidal gel plus condom ) Must able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Exclusion criterion : Have receive corticosteroid within 3 month start study symptom . Any eosinophilic disorder . History clinical schistosomiasis , travel within precede 6 month area endemic schistosomiasis , include limited Southeast Southwest Asia , South America Africa . Travel area must plan least 6 month last dose . Donation loss 400 ml blood within eight ( 8 ) week prior initial dosing . History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . History drug alcohol abuse within 12 month prior dose , evidence abuse indicate laboratory assay conduct screening . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Esophagitis</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Esophageal disorder</keyword>
	<keyword>Eosinophilic esophagitis</keyword>
</DOC>